ProCrysta Biologix, Inc. is dedicated to develop novel protein therapeutics for the treatment and prevention of infectious diseases and metabolic disorders through its proprietary crystallization technology. The technology has potential to bring breakthrough new treatments to patients with unmet medical needs.
ProCrysta’s proprietary crystallization technology designs effective protein therapeutics with a choice of delivery options; oral, subcutaneous, topical or pulmonary routes. As more biologics considered for therapy, high concentration and controlled release formulations become the key features for its successful development. ProCrysta's unparalleled technology can engender a unique opportunity for biologics formulation and delivery to improve the health and patient compliance.
ProCrysta is developing a novel protein therapy for the treatment of tuberculosis. This program is funded by NIH.